全文获取类型
收费全文 | 4727篇 |
免费 | 533篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 87篇 |
儿科学 | 27篇 |
妇产科学 | 432篇 |
基础医学 | 955篇 |
口腔科学 | 86篇 |
临床医学 | 225篇 |
内科学 | 145篇 |
皮肤病学 | 190篇 |
神经病学 | 3篇 |
特种医学 | 18篇 |
外科学 | 193篇 |
综合类 | 580篇 |
一般理论 | 1篇 |
预防医学 | 923篇 |
眼科学 | 2篇 |
药学 | 154篇 |
3篇 | |
中国医学 | 44篇 |
肿瘤学 | 1229篇 |
出版年
2024年 | 2篇 |
2023年 | 92篇 |
2022年 | 95篇 |
2021年 | 166篇 |
2020年 | 247篇 |
2019年 | 234篇 |
2018年 | 253篇 |
2017年 | 235篇 |
2016年 | 271篇 |
2015年 | 233篇 |
2014年 | 363篇 |
2013年 | 374篇 |
2012年 | 286篇 |
2011年 | 397篇 |
2010年 | 285篇 |
2009年 | 297篇 |
2008年 | 211篇 |
2007年 | 219篇 |
2006年 | 215篇 |
2005年 | 138篇 |
2004年 | 111篇 |
2003年 | 94篇 |
2002年 | 74篇 |
2001年 | 70篇 |
2000年 | 52篇 |
1999年 | 32篇 |
1998年 | 28篇 |
1997年 | 27篇 |
1996年 | 25篇 |
1995年 | 31篇 |
1994年 | 30篇 |
1993年 | 17篇 |
1992年 | 22篇 |
1991年 | 17篇 |
1990年 | 17篇 |
1989年 | 17篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有5297条查询结果,搜索用时 15 毫秒
1.
2.
目的:分析我院2020年1月1日至2020年9月中旬近4万余例女性HPV感染情况,为HPV疫苗接种、宫颈病变预防、治疗、随访提供流行病学数据。方法:选取我院2020年1月1日至2020年9月中旬之间,于我院妇科门诊及病房、皮肤科门诊及体检中心的37 325接受HPV分型检测的患者的临床资料,分析检测结果。结果:HPV感染率为13.91%(5 193/37 325),单一感染率11.46%(4 276/37 325),阳性构成比82.34%(4 276/5 193),高危亚型感染以HPV16最多见,其次52、58,低危型以6最多见,其次为11、44,与5年前HPV感染情况分析中最常见的低危亚型为cp8304不同。不同年龄段感染率不同。结论:近年沈阳地区妇女HPV感染率为13.91%,较5年前感染率18.60%有所下降,以单一、高危亚型感染为主,多重感染并存为特征。 相似文献
3.
4.
5.
The availability of human papillomavirus (HPV) vaccines and screening tests has raised the possibility of globally eliminating cervical cancer, which is caused by HPV. Cervical cancer is a very common malignancy worldwide, especially among deprived women. High vaccination coverage is key to the containment and eventual elimination of the infection. Public HPV vaccination programmes in Italy and Denmark were swiftly established and are among the most successful worldwide. Still, in both countries, it has been challenging to achieve and maintain the recommended coverage of > 80% in girls. In a well‐studied Italian region, vaccination coverage in girls at age 15 years (World Health Organization''s gold standard) reached 76% in 2015 but decreased to 69% in 2018, likely due to work overload in public immunization centres. In Denmark, doubts about safety and efficacy of the HPV vaccine generated a decline in coverage among girls age 12–17, from 80% in 2013 down to 37% in 2015, when remedial actions made it rise again. Insights from these two countries are shared to illustrate the importance of monitoring coverage in a digital vaccine registry and promptly reacting to misinformation about vaccination.
Abbreviations
- CC
- cervical cancer
- FVG
- Friuli Venezia Giulia
- HICs
- high‐income countries
- HPV
- human papillomavirus
- LMICs
- middle‐income countries
- WHO
- World Health Organization
6.
《Vaccine》2021,39(25):3388-3396
Dengue is endemic in several regions, and the global incidence is increasing. The recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) is recommended for dengue seropositive individuals ≥ 9 years. Human papillomavirus (HPV) vaccination is recommended for girls aged 9–14 years to prevent HPV infection-related cancers. This study assessed the immunogenicity and safety of a bivalent HPV (types 16 and 18) vaccine and CYD-TDV when co-administered concomitantly or sequentially.This was a Phase IIIb, randomized, open-label, multicenter study in girls aged 9–14 years in Mexico (NCT02979535). Participants were randomized 1:1 to receive three doses of CYD-TDV 6 months apart and two doses of bivalent HPV vaccine either concomitantly with, or 1 month before (sequentially), the first 2 CYD-TDV doses. Antibody levels were measured at baseline and 28-days after each vaccine dose for all participants, using an enzyme-linked immunosorbent assay for HPV-16 and HPV-18 antibodies, and a plaque reduction neutralization test for the four dengue serotypes; results are reported only for participants who were seropositive at baseline. Safety was assessed for all randomized participants throughout the study.Of the randomized participants, 305/478 (63.8%) were seropositive for dengue at baseline: 154 in the concomitant group and 151 in the sequential group. After the last HPV vaccine dose, the antibody titers for HPV were comparable in seropositive participants between treatment groups, with between group titer ratios of 0.966 for HPV-16 and 0.999 for HPV-18. After dose 3 of CYD-TDV, antibody titers were comparable for the concomitant and sequential groups across all serotypes, with between-group ratios close to 1 (serotype 1: 0.977; serotype 2: 0.911; serotype 3: 0.921; serotype 4: 0.931).CYD-TDV and a bivalent HPV vaccine administered concomitantly or sequentially in dengue seropositive girls aged 9–14 years elicited comparable immune responses with similar safety profiles. 相似文献
7.
8.
9.
10.